{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:19:00Z","timestamp":1781050740808,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.psyneuen.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T11:27:54Z","timestamp":1468841274000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis"],"prefix":"10.1016","volume":"73","author":[{"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Lammertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2016.07.009_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/clpt.1982.111","article-title":"Obesity, sex, and acetaminophen disposition","volume":"31","author":"Abernethy","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0010","first-page":"873","article-title":"Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen","volume":"101","author":"Abernethy","year":"1983","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2005-862617","article-title":"Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection","volume":"38","author":"Bader","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0025","unstructured":"Bader, W., 2009. Therapeutisches Drug Monitoring bei Antipsychotika: die Entwicklung der Analytik von Antipsychotika und ihre Relevanz bei der Therapieleitung schizophrener Patienten am Beispiel des Arzneistoffes Risperidon. Saska."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00007691-199902000-00017","article-title":"Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors","volume":"21","author":"Balant-Gorgia","year":"1999","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/hup.2420","article-title":"Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers","volume":"29","author":"Cabaleiro","year":"2014","journal-title":"Hum. Psychopharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.psyneuen.2016.07.009_bib0040","first-page":"S89","article-title":"Clinical review of risperidone","volume":"38","author":"Chouinard","year":"1993","journal-title":"Can. J. Psychiatry. Revue canadienne de psychiatrie"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":"The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A\/1B knockout mouse model","volume":"33","author":"Doran","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0055","doi-asserted-by":"crossref","first-page":"e23614","DOI":"10.1371\/journal.pone.0023614","article-title":"P-glycoprotein dysfunction contributes to hepatic steatosis and obesity in mice","volume":"6","author":"Foucaud-Vignault","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oxfordjournals.aje.a008733","article-title":"How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups?","volume":"143","author":"Gallagher","year":"1996","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0065","first-page":"238","article-title":"Arzneimitteltherapiesicherheit\/Pharmakovigilanz in der klinischen Psychopharmakotherapie-Das kliniknetzwerk AGATE","volume":"18","author":"Haen","year":"2011","journal-title":"Psychopharmakotherapie"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1286285","article-title":"Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety","volume":"44","author":"Haen","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0075","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1128\/AAC.05623-11","article-title":"Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0085","first-page":"13","article-title":"The pharmacokinetics of risperidone in humans: a summary","author":"Heykants","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0100","article-title":"Harmonised tripartite guideline, validation of analytical procedures: test and methodology","author":"ICH International Conference on Harmonisation","year":"1996","journal-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.thromres.2014.05.019","article-title":"The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study","volume":"134","author":"Jakubowski","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0110","series-title":"Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors","first-page":"497","article-title":"Overweight and obesity (high body mass index)","author":"James","year":"2004"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0120","first-page":"A23","article-title":"Konbest \u2013 a web-based laboratory information management system (LIMS) for TDM-Laboratories","volume":"41","author":"K\u00f6stlbacher","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","article-title":"Drug disposition in obesity: toward evidence-based dosing","volume":"55","author":"Knibbe","year":"2015","journal-title":"Annu. Rev. Pharmacool. Toxicol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0130","first-page":"8","article-title":"Effects of obesity on the cytochrome P450 enzyme system","volume":"37","author":"Kotlyar","year":"1999","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2125.2011.04159.x","article-title":"Therapeutic drug monitoring to adjust dosing in morbid obesity \u2013 a new use for an old methodology","volume":"73","author":"Martin","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0155","first-page":"214","article-title":"Low-Dose risperidone-Induced oculogyric crises in an adolescent male with autism, tourette's and developmental delay","volume":"20","author":"Masliyah","year":"2011","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry=Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine","volume":"33","author":"McAlpine","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40262-014-0154-1","article-title":"Levofloxacin dosing regimen in severely morbidly obese patients (BMI>\/=40kg\/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring","volume":"53","author":"Pai","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0170","first-page":"142","article-title":"Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch-toxikologischen Untersuchungen","volume":"76","author":"Paul","year":"2009","journal-title":"Toxichem Krimtech"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0175","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1345\/aph.1P745","article-title":"TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient","volume":"45","author":"Pea","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0180","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283498ecf","article-title":"Genetic epidemiology of induced CYP3A4 activity","volume":"21","author":"Rahmioglu","year":"2011","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side-effects","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0190","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-016-2085-2","article-title":"Pharmacokinetic patterns of risperidone \u2212associated adverse drug reactions","author":"Schoretsanitis","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0195","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfb.2011.03.035","article-title":"Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound","volume":"86","author":"Silva","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007691-200008000-00019","article-title":"Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate","volume":"22","author":"Spina","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/FTD.0b013e318219407a","article-title":"A comparison of folic acid pharmacokinetics in obese and nonobese women of childbearing age","volume":"33","author":"Stern","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0210","doi-asserted-by":"crossref","first-page":"e79603","DOI":"10.1371\/journal.pone.0079603","article-title":"Pharmacokinetics of drugs in cachectic patients: a systematic review","volume":"8","author":"Trobec","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0215","series-title":"Guidance for Industry on Biomedical Method Validation","author":"US Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0220","series-title":"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","author":"US Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10928-006-9040-2","article-title":"Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder","volume":"34","author":"Vermeulen","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0230","first-page":"A64","article-title":"Association between body weight and serum concentration of antidepressant drugs","volume":"25","author":"Warrings","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hup.1025","article-title":"Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia","volume":"24","author":"Yagihashi","year":"2009","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2016.07.009_bib0245","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1745-7254.2006.00256.x","article-title":"Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia","volume":"27","author":"Zhou","year":"2006","journal-title":"Acta Pharmacol. Sin."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453016302244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453016302244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:53:05Z","timestamp":1759683185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453016302244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":49,"alternative-id":["S0306453016302244"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2016.07.009","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}